Kevin McCulloch - Aug 1, 2024 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
President and Chief Operating Officer
Signature
/s/ Beth Hecht, as Attorney-in-Fact
Stock symbol
XERS
Transactions as of
Aug 1, 2024
Transactions value $
$0
Form type
4
Date filed
8/2/2024, 05:22 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Award $0 +150K +10.33% $0.00 1.6M Aug 1, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XERS Stock Appreciation Right Award $0 +200K $0.00 200K Aug 1, 2024 Common Stock 200K $2.43 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The award will vest in full on the two-year anniversary of the grant date.
F2 Upon exercise, the Stock Appreciation Right will be settled in cash.

Remarks:

President and Chief Operating Officer